Opthea Receives Positive Feedback from European Regulatory Agencies for the OPT-302 Clinical Program in wet AMD
MELBOURNE, AUSTRALIA--(Marketwired - Mar 20, 2017) - Opthea Limited (ASX: OPT), a developer of novel biologic therapies for the treatment of eye diseases, has concluded positive European scientific advice meetings with the United Kingdom's (UK) …